Mirum Pharmaceuticals, Inc.
https://mirumpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mirum Pharmaceuticals, Inc.
Orphans Account For More Than A Third Of EU New Drug Approvals In 2022
Last year, the European Commission approved a record 55 therapies containing a new active substance, including 21 medicines for rare diseases. Among them were a number of gene therapies for indications such as cancer and hemophilia.
Dengue Vaccine Qdenga & Nine Drugs Win EMA Thumbs Up
The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.
Albireo Ready To Seek Second Bylvay Indication In Alagille Syndrome
With Bylvay approved last year for progressive familial intrahepatic cholestasis, Albireo looks to add an estimated 25,000 addressable patients to IBAT inhibitor’s label with strong Phase III data in ALGS.
EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel
Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice